Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MMP3 | P08254 | 1/20 | 0.37 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
| ▸ | MMP8 | P22894 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | TPI1 | P60174 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9971733 | 0.85 | TPI1 (0.34) | TPI1 | |
| SCHEMBL11966757 | 0.81 | SMN1; SMN2 (0.39) | HPGDRAB9ASMN1; SMN2NPC1TPI1 | |
| SCHEMBL9971737 | 0.80 | TPI1 (0.31) | TPI1 | |
| SCHEMBL11966756 | 0.78 | — | — | |
| SCHEMBL26556407 | 0.78 | BBOX1 (0.37) | TSHR | |
| SCHEMBL11966759 | 0.77 | TSHR (0.31) | SMN1; SMN2TSHRLMNA | |
| SCHEMBL100397 | 0.77 | MVD (0.38) | HPGDSMN1; SMN2TSHRLMNAALDH1A1 | |
| SCHEMBL100398 | 0.74 | TSHR (0.40) | TSHR | |
| SCHEMBL12936165 | 0.74 | SAT1 (0.35) | — | |
| SCHEMBL11966760 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110021756-A1 | METHOD OF MANUFACTURING AN AFFINITY PARTICLE, AFFINITY PARTICLE, AND SEPARATION METHOD | SHISEIDO COMPANY, LTD. (JP) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021756-A1 | METHOD OF MANUFACTURING AN AFFINITY PARTICLE, AFFINITY PARTICLE, AND SEPARATION METHOD | FCGR1A, FCGR3B, FCGR2A | HPGD 4013/4885MMP1 3588/4885MMP2 2731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.